$66.18
-1.04-1.55%
近くで: -
$66.25
0.070.11%
時間外: Nov 7, 6:45 PM EDT
Comments
Loading...
アナリストの評価、目標株価、予想
Exact Sciences Corp のコンセンサス目標株価は $73.96 で、28 人のアナリストの評価に基づいています。最高値は $90（11 4, 2025 に TD Cowen が発表）、最安値は $46（8 7, 2025 に RBC Capital が発表）です。直近のアナリスト評価 3 件は Wells Fargo、TD Cowen、Baird により 11 5, 2025、11 4, 2025、11 4, 2025 に発表されました。Wells Fargo、TD Cowen、Baird の平均目標株価は $87.67 で、これらの最新評価から Exact Sciences Corp に対して 32.33% のupsideが示唆されています。
推奨アナリスト会社1
Wells Fargo
TD Cowen
Baird
Benchmark
Guggenheim
1アナリスト評価から算出
Exact Sciencesのアナリスト評価
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/05/2025 | 28.3% | Wells Fargo | $68 → $85 | Maintains | Overweight | |||
11/04/2025 | 35.85% | TD Cowen | $74 → $90 | Maintains | Buy | |||
11/04/2025 | 32.83% | Baird | $72 → $88 | Maintains | Outperform | |||
11/04/2025 | 13.21% | Benchmark | $60 → $75 | Maintains | Buy | |||
11/04/2025 | 13.21% | Guggenheim | $70 → $75 | Maintains | Buy | |||
11/04/2025 | 16.23% | Barclays | $65 → $77 | Maintains | Overweight | |||
11/04/2025 | 20.75% | Stifel | $67 → $80 | Maintains | Buy | |||
11/04/2025 | 28.3% | BTIG | $75 → $85 | Maintains | Buy | |||
10/22/2025 | 13.21% | BTIG | $60 → $75 | Maintains | Buy | |||
10/08/2025 | 5.66% | Piper Sandler | $60 → $70 | Maintains | Overweight | |||
10/07/2025 | 2.64% | Evercore ISI Group | $64 → $68 | Maintains | Outperform | |||
10/02/2025 | -1.89% | Barclays | $55 → $65 | Maintains | Overweight | |||
09/11/2025 | 28.3% | Craig-Hallum | $65 → $85 | Maintains | Buy | |||
08/12/2025 | -9.43% | BTIG | $65 → $60 | Maintains | Buy | |||
08/11/2025 | -9.43% | Piper Sandler | $70 → $60 | Maintains | Overweight | |||
08/08/2025 | -3.4% | Evercore ISI Group | $68 → $64 | Maintains | Outperform | |||
08/07/2025 | -20% | UBS | $61 → $53 | Maintains | Neutral | |||
08/07/2025 | -30.57% | RBC Capital | $54 → $46 | Maintains | Sector Perform | |||
08/07/2025 | -16.98% | Barclays | $65 → $55 | Maintains | Overweight | |||
07/08/2025 | 2.64% | Evercore ISI Group | $66 → $68 | Maintains | Outperform | |||
06/24/2025 | -1.89% | Barclays | $75 → $65 | Maintains | Overweight | |||
05/02/2025 | 13.21% | Barclays | $55 → $75 | Maintains | Overweight | |||
05/02/2025 | -18.49% | RBC Capital | $52 → $54 | Maintains | Sector Perform | |||
05/02/2025 | -0.38% | Evercore ISI Group | $60 → $66 | Maintains | Outperform | |||
05/02/2025 | 8.68% | Baird | $69 → $72 | Maintains | Outperform | |||
04/11/2025 | -9.43% | Guggenheim | $60 → $60 | Reiterates | Buy → Buy | |||
04/10/2025 | -16.98% | Barclays | $65 → $55 | Maintains | Overweight | |||
04/10/2025 | -9.43% | Mizuho | → $60 | Initiates | → Outperform | |||
03/13/2025 | -21.51% | RBC Capital | → $52 | Initiates | → Sector Perform | |||
02/26/2025 | 5.66% | Piper Sandler | $75 → $70 | Maintains | Overweight | |||
02/24/2025 | 10.19% | Scotiabank | $70 → $73 | Maintains | Sector Outperform | |||
02/20/2025 | -1.89% | B of A Securities | $72 → $65 | Maintains | Buy | |||
02/20/2025 | -1.89% | Barclays | $70 → $65 | Maintains | Overweight | |||
01/23/2025 | 5.66% | Barclays | → $70 | Initiates | → Overweight | |||
01/13/2025 | -1.89% | Benchmark | $65 → $65 | Reiterates | Buy → Buy | |||
12/13/2024 | 8.68% | B of A Securities | $75 → $72 | Maintains | Buy | |||
11/26/2024 | 29.81% | TD Cowen | $82 → $86 | Maintains | Buy | |||
11/26/2024 | 13.21% | BTIG | $65 → $75 | Maintains | Buy | |||
11/11/2024 | 13.21% | Piper Sandler | $85 → $75 | Maintains | Overweight | |||
11/06/2024 | 13.21% | Citigroup | $80 → $75 | Maintains | Buy | |||
11/06/2024 | 28.3% | Jefferies | $84 → $85 | Maintains | Buy | |||
11/06/2024 | -1.89% | BTIG | $82 → $65 | Maintains | Buy | |||
11/06/2024 | 1.13% | Stifel | $82 → $67 | Maintains | Buy | |||
11/06/2024 | 13.21% | Canaccord Genuity | $95 → $75 | Maintains | Buy | |||
11/06/2024 | 23.77% | TD Cowen | $90 → $82 | Maintains | Buy | |||
11/06/2024 | -1.89% | Goldman Sachs | $75 → $65 | Maintains | Buy | |||
11/06/2024 | -9.43% | Evercore ISI Group | $80 → $60 | Maintains | Outperform | |||
11/06/2024 | -1.89% | Craig-Hallum | $82 → $65 | Maintains | Buy | |||
11/06/2024 | -1.89% | Benchmark | $67 → $65 | Maintains | Buy | |||
11/06/2024 | 1.13% | Baird | $70 → $67 | Maintains | Outperform | |||
10/30/2024 | 35.85% | Bernstein | $75 → $90 | Maintains | Outperform | |||
10/29/2024 | 43.4% | Canaccord Genuity | $75 → $95 | Maintains | Buy | |||
10/01/2024 | 20.75% | Evercore ISI Group | $72 → $80 | Maintains | Outperform | |||
09/26/2024 | — | Raymond James | — | Reiterates | → Market Perform | |||
09/13/2024 | 13.21% | Canaccord Genuity | $75 → $75 | Maintains | Buy | |||
09/12/2024 | 28.3% | Piper Sandler | $75 → $85 | Maintains | Overweight | |||
08/27/2024 | 13.21% | Wells Fargo | → $75 | Initiates | → Overweight | |||
08/01/2024 | 1.13% | Benchmark | $91 → $67 | Maintains | Buy | |||
08/01/2024 | 23.77% | Stifel | $100 → $82 | Maintains | Buy | |||
07/17/2024 | 13.21% | Goldman Sachs | $88 → $75 | Maintains | Buy | |||
07/02/2024 | 8.68% | Evercore ISI Group | $80 → $72 | Maintains | Outperform | |||
06/27/2024 | 5.66% | BTIG | $80 → $70 | Maintains | Buy | |||
06/27/2024 | 5.66% | Scotiabank | → $70 | Initiates | → Sector Outperform | |||
06/26/2024 | 5.66% | BTIG | $80 → $70 | Maintains | Buy | |||
05/09/2024 | 20.75% | BTIG | $85 → $80 | Maintains | Buy | |||
05/09/2024 | 28.3% | Canaccord Genuity | $90 → $85 | Maintains | Buy | |||
05/09/2024 | 20.75% | Citigroup | $100 → $80 | Maintains | Buy | |||
04/03/2024 | 50.94% | Citigroup | → $100 | Maintains | Buy | |||
02/22/2024 | 35.85% | Canaccord Genuity | $100 → $90 | Maintains | Buy | |||
01/02/2024 | 37.36% | Benchmark | → $91 | Upgrade | Hold → Buy | |||
12/14/2023 | 35.85% | Guggenheim | → $90 | Initiates | → Buy | |||
12/13/2023 | — | Wolfe Research | — | Initiates | → Outperform | |||
11/03/2023 | 35.85% | Goldman Sachs | $100 → $90 | Maintains | Buy | |||
10/16/2023 | 20.75% | Piper Sandler | $90 → $80 | Maintains | Overweight | |||
10/10/2023 | 35.85% | Piper Sandler | → $90 | Upgrade | Neutral → Overweight | |||
09/28/2023 | 25.28% | Bernstein | → $83 | Initiates | → Outperform | |||
08/08/2023 | 35.85% | Piper Sandler | $80 → $90 | Maintains | Neutral | |||
08/03/2023 | 66.04% | Jefferies | $100 → $110 | Maintains | Buy | |||
08/02/2023 | 35.85% | Credit Suisse | $75 → $90 | Maintains | Neutral | |||
08/02/2023 | 82.64% | Baird | $99 → $121 | Maintains | Outperform | |||
08/02/2023 | — | Benchmark | — | Downgrade | Buy → Hold | |||
07/24/2023 | 66.04% | Goldman Sachs | $85 → $110 | Maintains | Buy | |||
07/21/2023 | 66.04% | Goldman Sachs | $85 → $110 | Maintains | Buy | |||
06/23/2023 | 73.58% | Canaccord Genuity | $92 → $115 | Maintains | Buy | |||
06/22/2023 | 96.23% | Citigroup | $100 → $130 | Maintains | Buy | |||
06/22/2023 | 44.91% | Benchmark | → $96 | Reiterates | Buy → Buy | |||
06/21/2023 | 28.3% | Stifel | → $85 | Reiterates | Buy → Buy | |||
06/21/2023 | 38.87% | Canaccord Genuity | → $92 | Reiterates | Buy → Buy | |||
06/07/2023 | 50.94% | Jefferies | $82 → $100 | Maintains | Buy | |||
05/11/2023 | 50.94% | Citigroup | $90 → $100 | Maintains | Buy | |||
05/10/2023 | 23.77% | Jefferies | $72 → $82 | Maintains | Buy | |||
05/10/2023 | 32.83% | B of A Securities | $80 → $88 | Maintains | Buy | |||
05/10/2023 | 13.21% | Credit Suisse | $70 → $75 | Maintains | Neutral | |||
05/10/2023 | 49.43% | Baird | $92 → $99 | Maintains | Outperform | |||
05/10/2023 | 28.3% | Craig-Hallum | $55 → $85 | Upgrade | Hold → Buy | |||
05/05/2023 | 10.19% | UBS | → $73 | Initiates | → Neutral | |||
03/15/2023 | 17.74% | Benchmark | $54 → $78 | Maintains | Buy | |||
03/09/2023 | 35.85% | Citigroup | $70 → $90 | Upgrade | Neutral → Buy | |||
03/03/2023 | 5.66% | Piper Sandler | $50 → $70 | Maintains | Neutral | |||
02/22/2023 | 14.72% | Cowen & Co. | $56 → $76 | Maintains | Outperform |
よくある質問
Exact Sciences (EXAS) 株の目標株価はいくらですか?
Exact Sciencesの最新目標株価Exact Sciences。(NASDAQ:EXAS) の最新目標株価をWells Fargoが11 5, 2025日に発表した。このアナリスト会社はExact Sciences ({{change}:{{mbol}}) {{{quoteName}}の{{change}:{{symbol}}からriseまで12ヶ月以内（28.30% upsideの可能性あり）と予想する$85.00の目標株価を設定しました。過去1年間に39のアナリスト会社がレーティングを報告しています。
Exact Sciences (Exact Sciencesの直近のアナリスト評価は？(EXAS) の直近のアナリスト評価は？
Exact Sciencesの最新のアナリストレーティングはExact Sciencesです。(NASDAQ:EXAS) の最新のアナリストレーティングはWells Fargoによるもので、Exact SciencesのExact Sciencesです。{actionCompany}}のoverweight評価です。
Exact Sciences (EXASの直近のアップグレードはいつですか？(EXAS) の最後のアップグレードはいつですか？
Exact Sciences Corpの最後のアップグレードは1 2, 2024日に行われ、Benchmarkは目標株価を$91に引き上げました。companyName}}のBenchmarkの以前のa holdは$91でした。
Exact Sciences (Exact Sciencesの直近の格下げ日はいつですか？(EXAS) の最後の格下げはいつですか？
Exact Sciences Corpの最後の格下げは8 2, 2023日にBenchmarkがExact Sciences Corpの目標株価をN/AからN/Aに変更した時です。
Exact Sciences (Exact Sciencesの次のアナリストレーティングはいつ発表・更新されますか？(EXAS) の次の格付けはいつですか？
アナリストは、公開財務諸表を調べたり、Exact Sciencesの役員や顧客に話を聞いたり、決算の電話会議を傍聴したりと、広範な調査を行った上で株価の格付けを行っています。ほとんどのアナリストは3ヶ月ごとにこの作業を行いますので、毎年1社につき4つの格付けを得ることになります。companyName}}の最終レーティングは11 5, 2025日に提出されましたので、次のレーティングは11 5, 2026日あたりに提出されるものと思われます。
Exact SciencesのアナリストレーティングはExact Sciencesですか？(EXAS) は正しいですか？
レーティングは主観的なものであり変化しますが、最新のExact Sciences (EXAS) (EXAS) のレーティングは維持で、目標株価は$68.00から$85.00でした。現在の価格 Exact Sciences ({{exchange}}) (EXAS) の現在の取引価格は$66.25で、これはアナリストの予測レンジout ofです。
ブラウズ アナリスト評価と目標株価 全銘柄の
こんな人も見ています
© 2025 Benzinga | All Rights Reserved